



February 18, 2008

Dear Baxter Valued Customer:

After thorough consideration, Baxter Healthcare Corporation has decided to discontinue the distribution of the select product codes included in this notification letter. Because of this, the select codes shall be deleted from all applicable G.P.O. agreements and individual contracts effective immediately. The select product codes are as follows:

NDC Number	Product Description
10019-873-15	ENLON (edrophonium chloride injection, USP) 10 mg/mL, 15 mL Vial
10019-180-05	ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection, 5 mL Ampul
10019-195-15	ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection, 15 mL Multi-Dose Vial

Due to the number of distribution channels which stock these select codes, inventory may continue to be available beyond the notification date of this letter. Please consult with your designated Distributor/Wholesaler provider as to the best product alternative for each of these codes.

Should you have any questions concerning this notification letter, please contact your local Baxter pharmacy specialist or your local GPO representative. If any of the codes are not applicable please disregard.

Sincerely,

Tom Progar
Senior Director,
Marketing Operations
Medication Delivery U.S. Region
Baxter Healthcare Corporation